Summit Corp. forms advisory board to aid development of drug

Summit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD).

Summit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD).

The board will be made up of six world-renowned scientists and clinicians with expertise in the field of neuromuscular diseases, and particularly DMD.

"We are absolutely delighted to have brought together these eminent thought leaders in neuromuscular diseases to form a world-class Advisory Board that will support our DMD programme," commented Glyn Edwards, Chief Executive Officer of Summit.

"Their expertise brings a deep insight into the disease and will provide invaluable input into future patient clinical trials to support the progression of our utrophin modulation programme, including our lead candidate SMT C1100."

Shares in the company have fallen almost 30% in the year-to-date, equal to 1.88p.

NR

Recommended

Should you buy Vodafone shares, or steer clear?
Share tips

Should you buy Vodafone shares, or steer clear?

Vodafone grew revenue by 4% and profit by 11% last year, and offers investors a 6.4% dividend yield. So should you buy Vodafone shares? Rupert Hargrea…
17 May 2022
Melrose Industries: a British manufacturer that is well-placed for recovery
Share tips

Melrose Industries: a British manufacturer that is well-placed for recovery

Melrose, the aerospace and automotive manufacturer, has been hit by the pandemic, but the shares are unduly cheap says David J Stevenson.
17 May 2022
Avoid easyJet shares – there are better airlines to invest in
Share tips

Avoid easyJet shares – there are better airlines to invest in

EasyJet used to be one of Europe’s most impressive airlines. But now it is facing challenges on all fronts and losing out to the competition. Rupert …
16 May 2022
Britain’s ten most-hated shares – w/e 13 May
Stocks and shares

Britain’s ten most-hated shares – w/e 13 May

Rupert Hargreaves looks at Britain's ten-most hated shares, and what short-sellers are looking right now.
16 May 2022

Most Popular

Get set for another debt binge as real interest rates fall
UK Economy

Get set for another debt binge as real interest rates fall

Despite the fuss about rising interest rates, they’re falling in real terms. That will blow up a wild bubble, says Matthew Lynn.
15 May 2022
High inflation will fade – here’s why
Inflation

High inflation will fade – here’s why

Many people expect high inflation to persist for a long time. But that might not be true, says Max King. Inflation may fall faster than expected – and…
13 May 2022
Is the oil market heading for a supply glut?
Oil

Is the oil market heading for a supply glut?

Many people assume that the high oil price is here to stay – and could well go higher. But we’ve been here before, says Max King. History suggests tha…
16 May 2022